Chronic cardiovascular and renal actions of leptin: role of adrenergic activity
- PMID: 11882597
- DOI: 10.1161/hy0202.104398
Chronic cardiovascular and renal actions of leptin: role of adrenergic activity
Abstract
This study was designed to determine the role of changes in adrenergic activity in mediating the chronic cardiovascular, renal, and metabolic actions of leptin. Male Sprague-Dawley rats were implanted with catheters for mean arterial pressure (MAP) and heart rate (HR) measurements and IV infusions of either vehicle (n= 7) or alpha- and beta-adrenergic receptor antagonists, terazosin and propranolol (10 mg/kg/d; n= 8) throughout the study. After control measurements, murine leptin was infused IV (1.0 microg/kg/min) for 7 days along with vehicle or adrenergic antagonists, followed by a 7-day recovery period. Leptin infusion significantly reduced food intake in control rats from 22.6 +/- 0.8 to 10.6 +/- 0.4 g/d and, in adrenergic blockade rats, from 22.6 +/- 0.8 to 13.2 +/- 0.8 g/d. Fasting plasma insulin decreased from 48 +/- 10 to 5 +/- 2 microU/mL in control rats and from 51+/- 9 to 9 +/- 2 microU/mL in adrenergic blockade rats during leptin infusion. Leptin infusion did not significantly alter glomerular filtration rate in either group. MAP and HR increased by 6 +/- 1 mm Hg and 23 +/- 7 bpm after 7 days of leptin infusion in control rats. However, in adrenergic blockade rats, leptin infusion did not significantly alter MAP (-1 +/- 1 mm Hg) and decreased, rather than increased, HR (-23 +/- 8 bpm). These results indicate that leptin-induced increases in blood pressure and tachycardia are mediated by increased adrenergic activity and support the concept that leptin may be an important link between obesity, increased sympathetic activity, and hypertension. However, the chronic effects of leptin on insulin and glucose regulation do not appear to be altered by alpha- and beta-adrenergic receptor blockade.
Similar articles
-
Role of adrenergic activity in pressor responses to chronic melanocortin receptor activation.Hypertension. 2004 Feb;43(2):370-5. doi: 10.1161/01.HYP.0000111836.54204.93. Epub 2004 Jan 5. Hypertension. 2004. PMID: 14707160
-
Role of hypothalamic melanocortin 3/4-receptors in mediating chronic cardiovascular, renal, and metabolic actions of leptin.Hypertension. 2004 Jun;43(6):1312-7. doi: 10.1161/01.HYP.0000128421.23499.b9. Epub 2004 May 3. Hypertension. 2004. PMID: 15123576
-
Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin.Hypertension. 2001 Feb;37(2 Pt 2):670-6. doi: 10.1161/01.hyp.37.2.670. Hypertension. 2001. PMID: 11230354
-
Role of sympathetic nervous system and neuropeptides in obesity hypertension.Braz J Med Biol Res. 2000 Jun;33(6):605-18. doi: 10.1590/s0100-879x2000000600001. Braz J Med Biol Res. 2000. PMID: 10829088 Review.
-
Adrenergic receptors: biphasic dose responses.Crit Rev Toxicol. 2001 Jul;31(4-5):523-38. doi: 10.1080/20014091111802. Crit Rev Toxicol. 2001. PMID: 11504179 Review.
Cited by
-
-2548G>A LEP Polymorphism Is Positively Associated with Increased Leptin and Glucose Levels in Obese Saudi Patients Irrespective of Blood Pressure Status.Medicina (Kaunas). 2022 Feb 24;58(3):346. doi: 10.3390/medicina58030346. Medicina (Kaunas). 2022. PMID: 35334523 Free PMC article.
-
Association Between Obesity and Chronic Kidney Disease: Multivariable Mendelian Randomization Analysis and Observational Data From a Bariatric Surgery Cohort.Diabetes. 2023 Apr 1;72(4):496-510. doi: 10.2337/db22-0696. Diabetes. 2023. PMID: 36657976 Free PMC article.
-
Obesity, kidney dysfunction and hypertension: mechanistic links.Nat Rev Nephrol. 2019 Jun;15(6):367-385. doi: 10.1038/s41581-019-0145-4. Nat Rev Nephrol. 2019. PMID: 31015582 Free PMC article. Review.
-
The metabolic syndrome and chronic kidney disease.Transl Res. 2017 May;183:14-25. doi: 10.1016/j.trsl.2016.12.004. Epub 2016 Dec 9. Transl Res. 2017. PMID: 28025032 Free PMC article. Review.
-
Leptin is an independent marker of metabolic syndrome in elderly adults with type 2 diabetes.Tzu Chi Med J. 2017 Apr-Jun;29(2):109-114. doi: 10.4103/tcmj.tcmj_31_17. Tzu Chi Med J. 2017. PMID: 28757776 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources